Avidity Partners Management LP Tango Therapeutics, Inc. Transaction History

Avidity Partners Management LP

  • $1.63 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$3.25 - $5.46 $195 - $327
60 Added 0.01%
813,700 $2.95 Million
Q2 2022

Aug 15, 2022
BUY
$3.86 - $8.01 $357,590 - $742,046
92,640 Added 12.85%
813,640 $3.69 Million
Q1 2022

May 16, 2022
BUY
$7.01 - $10.94 $112,160 - $175,040
16,000 Added 2.27%
721,000 $5.47 Million
Q4 2021

Feb 14, 2022
BUY
$9.55 - $14.29 $3.87 Million - $5.79 Million
405,000 Added 135.0%
705,000 $7.71 Million
Q3 2021

Nov 15, 2021
BUY
$9.56 - $17.3 $2.87 Million - $5.19 Million
300,000 New
300,000 $3.88 Million

Others Institutions Holding TNGX

# of Institutions
123
Shares Held
91.7M
Call Options Held
3.1K
Put Options Held
1.5K
View Full List

About Tango Therapeutics, Inc.

TNGX Quotes by TradingView
  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $268M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email